BRAF and neoplasm: Alternatively, MSI assays that enrich and sequence specific microsatellites can be used, keeping costs equivalent to or less than MSI FLA or IHC, whilst leveraging the scalability and automatability of NGS and multiplexed analysis of BRAF c.1799T > A. Such assays can reduce LS screening to one, low cost, high throughput tumour test prior to germline MMR gene testing of select cases, and could facilitate widespread deployment of current guidance [127,128,129].